The Chronic Progressive Repeated Measures (CPRM) Model for Clinical Trials Comparing Change Over Time in Quantitative Trait Outcomes
DOI:
https://doi.org/10.6000/1929-6029.2024.13.17Keywords:
Clinical trial design, Clinical trial sample size, Mixed model for repeated measures, Power calculationsAbstract
Repeated measures analysis is a common analysis plan for clinical trials comparing change over time in quantitative trait outcomes in treatment versus control. Mixed model for repeated measures (MMRM) assuming an unstructured covariance of repeated measures is the default statistical analysis plan, with alternative covariance structures specified in the event that the MMRM model with unstructured covariance does not converge. We here describe a parsimonious covariance structure for repeated measures analysis that is specifically appropriate for longitudinal repeated measures of chronic progressive conditions. This model has the parsimonious features of the mixed effects model with random slopes and intercepts, but without restricting the repeated measure means to be linear with time. We demonstrate with data from completed trials that this pattern of longitudinal trajectories spreading apart over time is typical of Alzheimer’s disease. We further demonstrate that alternative covariance structures typically specified in statistical analysis plans using MMRM perform poorly for chronic progressive conditions, with the compound symmetry model being anticonservative, and the autoregressive model being poorly powered. Finally, we derive power calculation formulas for the chronic progressive repeated measures model that have the advantage of being independent of the design of the pilot studies informing the power calculations. When data follow the pattern of a chronic progressive condition. These power formulas are also appropriate for sizing clinical trials using MMRM analysis with unstructured covariance of repeated measures.
References
Marquis S, Moore MM, Howieson DB, et al. Independent predictors of cognitive decline in healthy elderly persons. Arch Neurol 2002; 59(4): 601-606. https://doi.org/10.1001/archneur.59.4.601 DOI: https://doi.org/10.1001/archneur.59.4.601
Cooper C, Sommerlad A, Lyketsos CG, Livingston G. Modifiable predictors of dementia in mild cognitive impairment: a systematic review and meta-analysis. Am J Psychiatry 2015; 172(4): 323-334. https://doi.org/10.1176/appi.ajp.2014.14070878 DOI: https://doi.org/10.1176/appi.ajp.2014.14070878
Morris JC, Edland S, Clark C, et al. The consortium to establish a registry for Alzheimer’s disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer’s disease. Neurology 1993; 43(12): 2457-2465. https://doi.org/10.1212/WNL.43.12.2457 DOI: https://doi.org/10.1212/WNL.43.12.2457
Teri L, McCurry SM, Edland SD, Kukull WA, Larson EB. Cognitive decline in Alzheimer’s disease: a longitudinal investigation of risk factors for accelerated decline. J. Gerontol. A Biol Sci Med Sci 1995; 50A(1): M49-55. https://doi.org/10.1093/gerona/50A.1.M49 DOI: https://doi.org/10.1093/gerona/50A.1.M49
Mallinckrodt CH, Lane PW, Schnell D, Peng Y, Mancuso JP. Recommendations for the Primary Analysis of Continuous Endpoints in Longitudinal Clinical Trials. Ther Innov Regul Sci 2008; 42: 303-319. https://doi.org/10.1177/009286150804200402 DOI: https://doi.org/10.1177/009286150804200402
Dyck vCH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med 2023; 388(1): 9-21. https://doi.org/10.1056/NEJMoa2212948 DOI: https://doi.org/10.1056/NEJMoa2212948
Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimer’s Dis 2022; 9(2): 197-210. https://doi.org/10.14283/jpad.2022.30 DOI: https://doi.org/10.14283/jpad.2022.30
Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA 2023; 330(6): 512-527. https://doi.org/10.1001/jama.2023.13239 DOI: https://doi.org/10.1001/jama.2023.13239
Laird NM,Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38: 963-974. https://doi.org/10.2307/2529876 DOI: https://doi.org/10.2307/2529876
Zhao Y, Edland SD. Power formulas for mixed effects models with random slope and intercept comparing rate of change across groups. Int J Biostat 2021; 18(1): 173-182. https://doi.org/10.1515/ijb-2020-0107 DOI: https://doi.org/10.1515/ijb-2020-0107
Quinn JF, Raman R, Thomas RG, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 2010; 304(17): 1903-1911. https://doi.org/10.1001/jama.2010.1510 DOI: https://doi.org/10.1001/jama.2010.1510
Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352(23): 2379-2388. https://doi.org/10.1056/NEJMoa050151 DOI: https://doi.org/10.1056/NEJMoa050151
Pinheiro J, Bates D, DebRoy S, Sarkar D, R Core Team. nlme: Linear and Nonlinear Mixed Effects Models 2021; R package version 3.1-152.
Hu N, Mackey H, Thomas R. Power and sample size for random coefficient regression models in randomized experiments with monotone missing data. Biometrical Journal 2021; 63(4): 806-824. https://doi.org/10.1002/bimj.202000184 DOI: https://doi.org/10.1002/bimj.202000184
Lu K, Luo X, Chen PY. Sample size estimation for repeated measures analysis in randomized clinical trials with missing data. Int J Biostat 2008; 4(1): Article 9. https://doi.org/10.2202/1557-4679.1098 DOI: https://doi.org/10.2202/1557-4679.1098
Donohue MC, Edland SD. longpower: Power and sample size calculations for longitudinal data 2019; R package version 1.0-19.
Donohue MC, Langford O, Insel PS, et al. Natural cubic splines for the analysis of Alzheimer’s clinical trials. Pharm Stat 2023. https://doi.org/10.1002/alz.070862 DOI: https://doi.org/10.1002/pst.2285
Raket LL. Progression models for repeated measures: Estimating novel treatment effects in progressive diseases. Stat Med 2022; 41(28): 5537-5557. https://doi.org/10.1002/sim.9581 DOI: https://doi.org/10.1002/sim.9581
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Policy for Journals/Articles with Open Access
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work
Policy for Journals / Manuscript with Paid Access
Authors who publish with this journal agree to the following terms:
- Publisher retain copyright .
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work .
